Dossier
Shionogi
Coverage of Shionogi in the Nexus archive.
- Shionogi-Backed Apnimed Seeks to Raise $160 Million in US IPO
Apnimed Inc., a late-stage drug developer focused on sleep apnea, is seeking to raise as much as $160 million in a US initial public offering. The company is backed by Shionogi.